Изменение концепции лечения АГ при метаболическом синдроме: от препаратов выбора к оптимальной лекарственной комбинации

Метаболический синдром , артериальная гипертензия , комбинированная терапия , трандола-прил , верапамил

1. Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112; 2735-2752.

2.

3. Guidelines for the management of arterial hypertension. J Hypertension 2007; 25:1105-1187.

4.

5. Mancia G., Bombelli M., Corrao G. et alMetabolic Syndrome in the Pressioni ArterioseMonitorate E Loro Associazioni(PAMELA) Study:Daily Life Blood Pressure, Cardiac Damage, andPrognosis Hypertension 2007;49;40-47.

6.

7. Ford E.S. Prevalence of the metabolic syndromedefined by the International Diabetes Federationamong adults in the U.S. Diabetes Care. 2005;28:2745-2749.

8.

9. Mancia G., Parati G., Borghi C., Ghironzi G., Andriani E., Marinelli L., Valentini M., Tessari F., Ambrosioni E.; SMOOTH investigators. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens. 2006; 24:837-843.

10.

11. Mancia G., Volpe R., Boros S., Ilardi M., Giannattasio C. Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care. J Hypertens. 2004;22:51-57

12.

13. Симомнова Г.И., Печенкина Е.А., Щербакова Л.В., Никитин Ю.П. Распространенность метаболического синдрома и его компонентов в Сибири. Тезисы докладов конференции «Актуальные вопросы диагностики и лечения метаболического синдрома». Москва 2006, С. 17.

14.

15. Opei L., Schall R. Old antihypertenisves and new diabetes. J Hypertension 2004; 22:1453-1458.

16.

17. Messerli F., Grossman E., Leonetti G.Antihypertensive therapy and new onset diabetes.J Hypertens 2004; 22:1845-1847.

18.

19. Kurtz T.W., Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists: beyond the renin-angiotensin system. J Hypertension 2004;22:2253-2261.

20.

21. Yusuf S., Gerstein H., Hoogwert В. et al. Ramipril and the development of diabetes. JAMA 2001;286:1882-1885.

22.

23. Verdecchia P., Reboldi G., Angeli F. et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. PIUMA Hypertension 2004; 43: 963-969.

24.

25. Bakris George, Molitch M., Hewkin A. et al Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome Diabetes Care 29:2592-2597, 2006

26.

27. Schneider M., Lerch M., Papiri M., Buechel P., Boehlen L., Shaw S., Risen W., Weidmann P. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens. 1996;14(5):669-77.

28.

29. R Ferna'ndezl, JG Puig2, JC Rodry'guez-Pe'rez3, J Garridol and J Redon4 on behalf of the TRAVEND Study Group Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. Journal of Human Hypertension (2001) 15, 849-856

30.

31. Holzgreve H. Safety profile of combination of trandolapril and varapamil. J Hypertens 1997; 15: S51-S53.

32.